New drug aims to tame overactive immune response in sepsis

NCT ID NCT06694701

Ongoing Disease control Sponsor: Hellenic Institute for the Study of Sepsis Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests emapalumab, a drug that blocks a protein called interferon-gamma, in 75 adults with sepsis caused by a specific immune overreaction. The goal is to see if the drug can reduce organ failure, measured by a drop in the SOFA score. Participants are in ICUs across Greece and receive either emapalumab or a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Emapalumab (a drug that blocks interferon-gamma, a protein involved in inflammation)
What this could lead to: If it works, this could point toward a targeted treatment for a specific type of sepsis, potentially reducing organ failure and improving survival in ICU patients.
What could go wrong: This is an early phase 2 trial with only 75 participants, so results may not apply to all sepsis patients. The drug may not improve outcomes or could cause side effects like increased infection risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Infections infectious disease with sepsis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEPSIS

Contacts and locations

Locations

1st Department of Internal Medicine, Thriasio Elefsis General Hospital

Elefsina, Attica, Greece
1st Intensive Care Unit, G. Papanikolaou Thessaloniki General Hospital

Thessaloniki, Greece
3rd University Department of Internal Medicine, Sotiria Chest Diseases Athens General Hospital

Athens, Greece
4th Department of Internal Medicine, ATTIKON University General Hospital

Athens, Greece
Clinic of Intensive Care and Pulmonary Diseases, Aghioi Anargyroi Kifissia General Oncologic Hospital

Kifissia, Attica, Greece
Department of Anesthesiology and Intensive Care, AHEPA Thessaloniki University General Hospital

Thessaloniki, Greece
Intensive Care Unit I, KAT Attica General Hospital

Athens, Greece
Intensive Care Unit of 1st University Department Respiratory Medicine, Sotiria Chest Diseases Athens General Hospital

Athens, Greece
Intensive Care Unit of Center for Respiratory Failure, Sotiria Chest Diseases Athens General Hospital

Athens, Greece
Intensive Care Unit, 424 General Military Training Hospital

Thessaloniki, Greece
Intensive Care Unit, Aghios Dimitrios Thessaloniki General Hospital

Thessaloniki, Greece
Intensive Care Unit, Alexandroupolis University General Hospital

Alexandroupoli, Greece
Intensive Care Unit, Asklipieio Voulas General Hospital

Athens, Greece
Intensive Care Unit, G. Gennimatas Thessaloniki General Hospital

Thessaloniki, Greece
Intensive Care Unit, Ippokrateio Athens General Hospital

Athens, Greece
Intensive Care Unit, Ippokrateio Thessaloniki General Hospital

Thessaloniki, Greece
Intensive Care Unit, Korgialeneio-Benakeio HRC Athens General Hospital

Athens, Greece
Intensive Care Unit, Laiko Athens General Hospital

Athens, Greece
Intensive Care Unit, Papageorgiou Thessaloniki General Hospital

Thessaloniki, Greece
Intensive Care Unit, Patras University General Hospital

Pátrai, Greece
Intensive Care Unit, Theageneio Thessaloniki Cancer Hospital

Thessaloniki, Greece
Intensive Care Unit, University General Hospital of Heraklion

Heraklion, Crete, Greece
New Multivalent Intensive Care Unit, Sotiria Chest Diseases Athens General Hospital

Athens, Greece
Ηigh Dependency Unit of Department of Clinical Therapeutics, Alexandra Athens General Hospital

Athens, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.